CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane
June 23, 2018
(Length of Discussion: 30 min)
Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical application of the findings of CARMENA as well as comparing the results with that of another study, SURTIME, an EROTC presented at EUA 2018.
Next, Tom Keane reviews Dr. Gary Sternberg’s ASCO 2018 presentation of Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer. In this multi-disciplinary session focused on bladder cancer, 3 specific patient cases were addressed. He begins with an overview of the initial patient presentation and moves through each case highlighting the surgical management options for each.
Biographies:
Thomas E. Keane, MBBCh, FRCSI, FACS
Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical application of the findings of CARMENA as well as comparing the results with that of another study, SURTIME, an EROTC presented at EUA 2018.
Next, Tom Keane reviews Dr. Gary Sternberg’s ASCO 2018 presentation of Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer. In this multi-disciplinary session focused on bladder cancer, 3 specific patient cases were addressed. He begins with an overview of the initial patient presentation and moves through each case highlighting the surgical management options for each.
Biographies:
Thomas E. Keane, MBBCh, FRCSI, FACS
Referenced in this discussion:
CARMENA: Cytoreductive Nephrectomy Followed by Sunitinib vs. Sunitinib Alone in Metastatic Renal Cell Carcinoma - Results of a Phase III Noninferiority Trial
Surgical Safety of Immediate versus Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma - SURTIME
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
CheckMate 214 Characterization of the Benefit-Risk Profile of Nivolumab + Ipilimumab Sunitinib for Treatment-Naïve Advanced RCC
Heng et al. EU 2014, Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
Bimal Bhindi Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma, The Journal of Urology, 2018 Mar 2
Gary Sternberg, MD 2018 ASCO Presentation Highlighted in Discussion: Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer
CARMENA: Cytoreductive Nephrectomy Followed by Sunitinib vs. Sunitinib Alone in Metastatic Renal Cell Carcinoma - Results of a Phase III Noninferiority Trial
Surgical Safety of Immediate versus Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma - SURTIME
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
CheckMate 214 Characterization of the Benefit-Risk Profile of Nivolumab + Ipilimumab Sunitinib for Treatment-Naïve Advanced RCC
Heng et al. EU 2014, Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
Bimal Bhindi Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma, The Journal of Urology, 2018 Mar 2
Gary Sternberg, MD 2018 ASCO Presentation Highlighted in Discussion: Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer